A Phase 4 interventional study of Apixaban and Parenteral heparin and/or oral Vitamin K antagonist in Atrial Fibrillation, sponsored by Pfizer. Completed at 165 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-05-23.
Sponsored by Pfizer · Phase 4, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies testing apixaban in Atrial Fibrillation — 11 open to participants now, 12 under way, 4 of them phase 3. apixaban · Atrial Fibrillation.
Among the 31 studies testing apixaban in Atrial Fibrillation, this one is the 8th largest by enrollment, is one of 5 that started in 2014, is one of 14 in phase 4, and was the 6th registered.
4,011 studies on the registry are indexed under Atrial Fibrillation; 960 are open to participants now.
Browse Atrial Fibrillation studies →11 of the 31 studies testing apixaban in Atrial Fibrillation are open now, in 10 countries. Recruiting first, the newest first:
Yonsei University · Sites in Korea, Republic of
Ages 19+
VA Office of Research and Development · Sites in United States
Ages 22+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 65+
Ottawa Hospital Research Institute · Sites in Canada
Ages 18+
Yonsei University · Sites in Korea, Republic of
Ages 19–80
By country, each count listing its studies:
apixaban: first FDA approval 2012 (ELIQUIS), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 611 Atrial Fibrillation studies recruiting now, 407 (67%) set no upper age limit and 43 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 5 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,500 is above the median of 150 across 2,476 interventional studies indexed under Atrial Fibrillation.
Median enrollment 586 across the 31 interventional studies. Of the 17 that completed or were terminated, 9 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 31 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
15 studies in Atrial Fibrillation by Pfizer: none open now, none under way, none of them phase 3. Of 13 finished, 10 (77%) have results posted.
Among the 15 studies in Atrial Fibrillation by Pfizer, this one is the only one that started in 2014, is the only one in phase 4, and was the 3rd registered.
Pfizer’s Atrial Fibrillation studies by the year they started, since 2000.
2 of the studies testing apixaban in Atrial Fibrillation that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03907046Phase 3Yale UniversityAnticoagulation in ICH Survivors for Stroke Prevention and Recovery | 2027-04 |
| NCT03129490Herlev and Gentofte HospitalThe Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Atrial Fibrillation | 2027-10-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 31 studies testing apixaban in Atrial Fibrillation, from their registry updates:
Among Pfizer’s 15 in Atrial Fibrillation:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Some people can develop an abnormal heart beat known as "Atrial fibrillation" or "AF" that puts them at risk of developing clots in the heart. Those clots can travel in the blood circulation to the brain and cause a brain attack ("a stroke"). To prevent those clots forming, blood thinners (anti-coagulants) are used. Apixaban is a blood thinner that works by stopping one of the blood substances required for clotting ("Factor Xa"). It is approved and used to prevent clots forming in people with "AF". Other established blood thinners work by stopping clotting substances being made, known as "Vitamin K antagonists" or "VKAs". An example of this type is Warfarin (Coumadin). The good effects of all blood thinners are preventing clots, and they may also have bad effects of increasing the chance of bleeding. People with "AF", abnormal heart beat, may benefit from changing it back to a normal regular rhythm, known medically as "cardioversion". When this is done, people are currently most commonly treated with a "VKA" blood thinner (e.g. warfarin). The purpose of this study is to assess the good and bad effects ("efficacy" and "safety") of apixaban compared with warfarin in people with "AF" in whom an early cardioversion is planned.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Apixaban
Parenteral heparin and/or locally used oral Vitamin K antagonist e.g. warfarin (excludes other novel oral anticoagulants)
Drug: Parenteral heparin and/or oral Vitamin K antagonist
Oral, 2.5 or 5 mg BID
Parenteral heparin and/or locally used oral Vitamin K antagonist e.g. warfarin (excludes other novel oral anticoagulants)
Number of Participants With Acute Stroke Event
An acute stroke was defined as a new, important neurological insufficiency of rapid onset that lasted for at least 24 hours and that was not due to a readily identifiable non-vascular cause (like brain tumor or trauma).
Time frame: Baseline up to 30 days post cardioversion (or up to 90 days after randomization, if cardioversion was not performed within that time frame)
Number of Participants With Systemic Embolism Event
Systemic embolism occurred in participant when there was a clinical history consistent with an acute loss of blood flow to a peripheral artery (or arteries), which was supported by evidence of embolism from surgical specimens, autopsy, angiography, or other objective testing.
Time frame: Baseline up to 30 days post cardioversion (or up to 90 days after randomization, if cardioversion was not performed within that time frame)
Number of Participants With Major Bleeding Event
Major bleeding was defined as clinically evident bleeding that was accompanied by one or more of the following: a decrease in hemoglobin of 2 gram per deciliter or more, a transfusion of 2 or more units of packed red blood cells, bleeding that was fatal or bleeding that occurred in at least one of the following critical sites: intracranial, intra-spinal, intraocular (within the corpus of the eye; thus, a conjunctival bleed was not an intraocular bleed), pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal.
Time frame: Baseline up to 30 days post cardioversion (or up to 90 days after randomization, if cardioversion was not performed within that time frame)
Number of Participants With Clinically Relevant Non-Major Bleeding Events
Clinically relevant non-major bleeding was defined as the clinically evident bleeding that consisted of any bleeding that compromised hemodynamics, that led to hospitalization, subcutaneous hematoma larger than 25/100 centimeter square if there was a traumatic cause, intramuscular hematoma documented by ultrasonography, epistaxis, gingival bleeding occurred spontaneously, hematuria that was macroscopic and was spontaneous, macroscopic gastrointestinal hemorrhage included at least one episode of melena or hematemesis, rectal blood loss, hemoptysis or any other bleeding type considered to have clinical consequences for a participant, such as medical intervention, the need for unscheduled contact with a physician, or temporary cessation of a study drug, or associated with pain or impairment of activities of daily life.
Time frame: Baseline up to 30 days post cardioversion (or up to 90 days after randomization, if cardioversion was not performed within that time frame)
Number of Participants With All Cause Death
Time frame: Baseline up to 30 days post cardioversion (or up to 90 days after randomization, if cardioversion was not performed within that time frame)
Time to First Attempt of Cardioversion
Cardioversion was an effective method of converting an abnormally fast heart rate (tachycardia) or other cardiac arrhythmia to normal rhythm using electricity or drugs. First attempt of cardioversion was defined as the first time the participant was admitted for the cardioversion procedure.
Time frame: Baseline up to Day of first attempt of cardioversion procedure (Visit 2, up to 130 days)
Number of Participants With Different Type of Cardioversion Events
Cardioversion was an effective method of converting an abnormally fast heart rate (tachycardia) or other cardiac arrhythmia to normal rhythm using different type of cardioversion events i.e. electrical and pharmacologic. Electrical cardioversion was a procedure in which an electric current was used to reset the heart's rhythm back to its regular pattern (normal sinus rhythm). Pharmacologic cardioversion, also called chemical cardioversion, used antiarrhythmia medication instead of an electrical shock.
Time frame: Baseline up to Day of first attempt of cardioversion procedure (Visit 2, up to 130 days)
Number of Cardioversion Attempt of Participants
Cardioversion attempts were defined as the number of times the participant was admitted to hospital for the cardioversion procedure and not the number of attempts during a single hospital admission.
Time frame: Baseline up to Day of first attempt of cardioversion procedure (Visit 2, up to 130 days)
Number of Participants With Their Rhythm Status
Rhythm status was further distinguished into sinus rhythm, atrial fibrillation and atrial flutter. Sinus rhythm was defined as a normal heartbeat. Atrial fibrillation was an irregular heartbeat (arrhythmia) that can lead to blood clots, stroke, heart failure and other heart-related complications and atrial flutter was a common abnormal heart rhythm that was usually associated with a fast heart rate (100 or more heart beats per minute).
Time frame: Baseline up to Day of first attempt of cardioversion procedure (Visit 2, up to 130 days)
Duration of Hospital Stay of Participants
Duration of hospital stay was defined as the number of hours from hospital admission to hospital discharge followed by early cardioversion.
Time frame: Baseline up to Day of first attempt of cardioversion procedure (Visit 2, up to 130 days)
Number of Participants Who Used Image Guidance Approach
An image-guided approach helped cardioversion earlier than the conventional minimum of 3 weeks of anticoagulation that would normally be required prior to cardioversion. Transesophageal echocardiography (TEE or TOE) and computed tomography (CT) were 2 image-guided approaches that were used in this study.
Time frame: Baseline up to Day of first attempt of cardioversion procedure (Visit 2, up to 130 days)
| Milestone | Apixaban | Parenteral Heparin/Oral Vitamin K Antagonist (Usual Care) |
|---|---|---|
| Started | 753 | 747 |
| Completed | 678 | 657 |
| Not completed | 75 | 90 |
| Withdrew: Other | 19 | 19 |
| Withdrew: Administrative reason | 0 | 1 |
| Withdrew: Inclusion/exclusion criteria not met | 12 | 16 |
| Withdrew: Non-compliance | 0 | 3 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Withdrawal by subject | 27 | 37 |
| Withdrew: Adverse event | 16 | 12 |
| Withdrew: Death | 1 | 1 |
An acute stroke was defined as a new, important neurological insufficiency of rapid onset that lasted for at least 24 hours and that was not due to a readily identifiable non-vascular cause (like brain tumor or trauma).
| participants | Apixaban | Parenteral Heparin/Oral Vitamin K Antagonist (Usual Care) |
|---|---|---|
| Number of Participants With Acute Stroke Event | 0 | 6 |
Systemic embolism occurred in participant when there was a clinical history consistent with an acute loss of blood flow to a peripheral artery (or arteries), which was supported by evidence of embolism from surgical specimens, autopsy, angiography, or other objective testing.
| participants | Apixaban | Parenteral Heparin/Oral Vitamin K Antagonist (Usual Care) |
|---|---|---|
| Number of Participants With Systemic Embolism Event | 0 (0 to 0) | 0 (0 to 0) |
Major bleeding was defined as clinically evident bleeding that was accompanied by one or more of the following: a decrease in hemoglobin of 2 gram per deciliter or more, a transfusion of 2 or more units of packed red blood cells, bleeding that was fatal or bleeding that occurred in at least one of the following critical sites: intracranial, intra-spinal, intraocular (within the corpus of the eye; thus, a conjunctival bleed was not an intraocular bleed), pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal.
| participants | Apixaban | Parenteral Heparin/Oral Vitamin K Antagonist (Usual Care) |
|---|---|---|
| Number of Participants With Major Bleeding Event | 3 | 6 |
Clinically relevant non-major bleeding was defined as the clinically evident bleeding that consisted of any bleeding that compromised hemodynamics, that led to hospitalization, subcutaneous hematoma larger than 25/100 centimeter square if there was a traumatic cause, intramuscular hematoma documented by ultrasonography, epistaxis, gingival bleeding occurred spontaneously, hematuria that was macroscopic and was spontaneous, macroscopic gastrointestinal hemorrhage included at least one episode of melena or hematemesis, rectal blood loss, hemoptysis or any other bleeding type considered to have clinical consequences for a participant, such as medical intervention, the need for unscheduled contact with a physician, or temporary cessation of a study drug, or associated with pain or impairment of activities of daily life.
| participants | Apixaban | Parenteral Heparin/Oral Vitamin K Antagonist (Usual Care) |
|---|---|---|
| Number of Participants With Clinically Relevant Non-Major Bleeding Events | 11 | 13 |
| participants | Apixaban | Parenteral Heparin/Oral Vitamin K Antagonist (Usual Care) |
|---|---|---|
| Number of Participants With All Cause Death | 2 | 1 |
Cardioversion was an effective method of converting an abnormally fast heart rate (tachycardia) or other cardiac arrhythmia to normal rhythm using electricity or drugs. First attempt of cardioversion was defined as the first time the participant was admitted for the cardioversion procedure.
| days | Apixaban | Parenteral Heparin/Oral Vitamin K Antagonist (Usual Care) |
|---|---|---|
| Time to First Attempt of Cardioversion | 2.0 (1 to 93) | 2.0 (1 to 126) |
Cardioversion was an effective method of converting an abnormally fast heart rate (tachycardia) or other cardiac arrhythmia to normal rhythm using different type of cardioversion events i.e. electrical and pharmacologic. Electrical cardioversion was a procedure in which an electric current was used to reset the heart's rhythm back to its regular pattern (normal sinus rhythm). Pharmacologic cardioversion, also called chemical cardioversion, used antiarrhythmia medication instead of an electrical shock.
| participants | Apixaban | Parenteral Heparin/Oral Vitamin K Antagonist (Usual Care) |
|---|---|---|
| Electrical | 461 | 464 |
| Pharmacologic | 35 | 30 |
Cardioversion attempts were defined as the number of times the participant was admitted to hospital for the cardioversion procedure and not the number of attempts during a single hospital admission.
| participants | Apixaban | Parenteral Heparin/Oral Vitamin K Antagonist (Usual Care) |
|---|---|---|
| No Cardioversion Attempt | 234 | 224 |
| 1 Cardioversion Attempt | 488 | 496 |
| More than 2 Cardioversion Attempts | 31 | 27 |
Rhythm status was further distinguished into sinus rhythm, atrial fibrillation and atrial flutter. Sinus rhythm was defined as a normal heartbeat. Atrial fibrillation was an irregular heartbeat (arrhythmia) that can lead to blood clots, stroke, heart failure and other heart-related complications and atrial flutter was a common abnormal heart rhythm that was usually associated with a fast heart rate (100 or more heart beats per minute).
| participants | Apixaban | Parenteral Heparin/Oral Vitamin K Antagonist (Usual Care) |
|---|---|---|
| Normal Sinus | 1 | 2 |
| Atrial Fibrillation | 715 | 704 |
| Atrial Flutter | 3 | 6 |
Duration of hospital stay was defined as the number of hours from hospital admission to hospital discharge followed by early cardioversion.
| hours | Apixaban | Parenteral Heparin/Oral Vitamin K Antagonist (Usual Care) |
|---|---|---|
| Duration of Hospital Stay of Participants | 45.36 (0.4 to 747.0) | 49.47 (0.6 to 709.6) |
An image-guided approach helped cardioversion earlier than the conventional minimum of 3 weeks of anticoagulation that would normally be required prior to cardioversion. Transesophageal echocardiography (TEE or TOE) and computed tomography (CT) were 2 image-guided approaches that were used in this study.
| participants | Apixaban | Parenteral Heparin/Oral Vitamin K Antagonist (Usual Care) |
|---|---|---|
| Number of Participants Who Used Image Guidance Approach | 383 | 399 |
Collected over From baseline up to 30 days after cardioversion or 90 days after randomization, if cardioversion was not performed. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Apixaban | 1/735 (0.1%) | 100/735 (13.6%) | 70/735 (9.5%) |
| Parenteral Heparin/Oral Vitamin K Antagonist (Usual Care) | 3/721 (0.4%) | 112/721 (15.5%) | 101/721 (14%) |
| Event | Apixaban | Parenteral Heparin/Oral Vitamin K Antagonist (Usual Care) |
|---|---|---|
| ATRIAL FIBRILLATIONCardiac disorders | 27/735 | 40/721 |
| CARDIAC FAILURE CONGESTIVECardiac disorders | 9/735 | 7/721 |
| CARDIAC FAILURECardiac disorders | 5/735 | 7/721 |
| ATRIAL FLUTTERCardiac disorders | 3/735 | 6/721 |
| CORONARY ARTERY DISEASECardiac disorders | 2/735 | 6/721 |
| PNEUMONIAInfections and infestations | 3/735 | 5/721 |
| ACUTE KIDNEY INJURYRenal and urinary disorders | 1/735 | 5/721 |
| ATRIAL THROMBOSISCardiac disorders | 0/735 | 3/721 |
| MITRAL VALVE PROLAPSECardiac disorders | 0/735 | 3/721 |
| OVERDOSEInjury, poisoning and procedural complications | 0/735 | 3/721 |
| Event | Apixaban | Parenteral Heparin/Oral Vitamin K Antagonist (Usual Care) |
|---|---|---|
| ATRIAL FIBRILLATIONCardiac disorders | 43/735 | 46/721 |
| INTERNATIONAL NORMALISED RATIO INCREASEDInvestigations | 0/735 | 27/721 |
| INTERNATIONAL NORMALISED RATIO ABNORMALInvestigations | 0/735 | 19/721 |
| ATRIAL THROMBOSISCardiac disorders | 17/735 | 13/721 |
| DYSPNOEARespiratory, thoracic and mediastinal disorders | 15/735 | 8/721 |
Full analysis set included all randomized participants.
| Age, Continuous(years) | Apixaban | Parenteral Heparin/Oral Vitamin K Antagonist (Usual Care) | Total |
|---|---|---|---|
| Mean | 64.7 ± 12.19 | 64.5 ± 12.76 | 64.6 ± 12.47 |
| Sex: Female, Male(Participants) | Apixaban | Parenteral Heparin/Oral Vitamin K Antagonist (Usual Care) | Total |
|---|---|---|---|
| Female | 248 | 250 | 498 |
| Male | 505 | 497 | 1002 |
| Ethnicity (NIH/OMB)(Participants) | Apixaban | Parenteral Heparin/Oral Vitamin K Antagonist (Usual Care) | Total |
|---|---|---|---|
| Hispanic or Latino | 8 | 9 | 17 |
| Not Hispanic or Latino | 100 | 99 | 199 |
| Unknown or Not Reported | 645 | 639 | 1284 |
| Race/Ethnicity, Customized(Participants) | Apixaban | Parenteral Heparin/Oral Vitamin K Antagonist (Usual Care) | Total |
|---|---|---|---|
| White | 654 | 648 | 1302 |
| Black or African American | 21 | 20 | 41 |
| Asian | 78 | 76 | 154 |
| Other | 0 | 3 | 3 |
Showing the first 100 of 165 sites across 12 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jul 2014 to primary completion in Feb 2017, 30 months.
Results were first posted in Apr 2018, 1 year 2 months after primary completion.
Of 141 phase 4 interventional studies under Atrial Fibrillation, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 81. This study's 30 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Apixaban